News - Velcade, Takeda Pharmaceuticals

Filter

Popular Filters

Strong results from meta-analysis of Takeda's Velcade in multiple myeloma

08-04-2013

Millennium, the USA-based oncology unit of Japan's largest drugmaker Takeda Pharmaceutical (TSE:4502),…

Millennium PharmaceuticalsOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

New molecule to target pancreatic cancer treatment found by Mayo Clinic researchers

06-01-2013

A new target to improve treatment of pancreatic ductal adenocarcinoma cancer, which accounts for more…

bortezomibJohnson & JohnsonOncologyPharmaceuticalResearchTakeda PharmaceuticalsVelcade

Multiple myeloma drug market forecast to reach $7.2 billion in 2021

03-10-2012

The multiple myeloma drug market will experience significant growth, increasing from $4.4 billion in…

BiotechnologyCelgeneGlobalJohnson & JohnsonMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

5.6% annual growth forecast for multiple myeloma drug market to 2020

21-12-2011

Driven by further penetration of Celgene’s Revlimid (lenalidomide) into the first-line setting and…

CelgeneGlobalJanssen-CilagMarkets & MarketingOncologyPharmaceuticalRevlimidTakeda PharmaceuticalsVelcade

Back to top